10-Q: Pulse Biosciences Reports Q3 2024 Results, Highlights Progress in Atrial Fibrillation and Soft Tissue Ablation

Pulse Biosciences reports its Q3 2024 financial results, emphasizing advancements in its atrial fibrillation and soft tissue ablation programs, while continuing to operate without significant revenue.

Summary

• Pulse Biosciences, a bioelectric medicine company, released its financial results for the third quarter of 2024, showing a net loss of $12.68 million, compared to a net loss of $10.57 million in the same period last year.
• The company's operating expenses totaled $13.66 million for the quarter, with research and development expenses at $7.70 million and general and administrative expenses at $5.95 million.
• For the nine months ended September 30, 2024, the net loss was $34.2 million, compared to $30.28 million for the same period in 2023.
• The company's cash and cash equivalents stood at $79.03 million as of September 30, 2024, up from $44.37 million at the end of 2023, primarily due to a recent rights offering.
• Pulse Biosciences continues to focus on the development of its Nano-pulse Stimulation (NPS) technology, particularly in the treatment of atrial fibrillation (AF) and soft tissue ablation.
• The company has received FDA 510(k) clearance for its CellFX nsPFA Percutaneous Electrode System for soft tissue ablation and has initiated a first-in-human study for thyroid nodule treatment.
• A multi-site clinical study for the cardiac surgical ablation clamp has commenced in the Netherlands, and a clinical study for the CellFX nsPFA 360 Cardiac Catheter is underway in Prague, Czech Republic.
• The company expects to begin pivotal clinical trials for both the cardiac clamp and catheter in mid-2025.

Sentiment

Score: 5

Explanation: The document presents a mixed picture. While there is positive progress in clinical trials and regulatory approvals, the company continues to operate at a loss and relies on capital raises. The sentiment is neutral to slightly negative due to the ongoing financial losses and dependence on future funding.

Positives

• The company successfully raised $60 million through a rights offering, significantly increasing its cash position.
• FDA clearance for the CellFX nsPFA Percutaneous Electrode System allows for commercialization in the U.S. for soft tissue ablation.
• The first-in-human study for thyroid nodule treatment has shown promising results with no serious side effects reported.
• The company has initiated clinical studies for both its cardiac surgical ablation clamp and cardiac endocardial ablation catheter.
• The Breakthrough Device Designation and enrollment in the FDA's TAP program could expedite the development and review of the cardiac surgery system.

Negatives

• The company continues to operate at a loss, with a net loss of $12.68 million for Q3 2024 and $34.2 million for the nine months ended September 30, 2024.
• The company has not generated any revenue from product sales during the reported periods.
• The company is dependent on additional capital raises to fund its operations and product development.
• The company has limited experience in commercializing medical devices, particularly in the cardiology space.

Risks

• The company's future success is heavily dependent on the successful development and commercialization of its NPS technology.
• The company faces intense competition from well-established medical device companies.
• Clinical trials may not demonstrate the safety and efficacy of the company's product candidates.
• Regulatory approvals may be delayed or not granted, which could hinder commercialization efforts.
• The company may not be able to obtain adequate reimbursement for its products from third-party payers.
• The company is dependent on third-party manufacturers and suppliers for critical components.
• The company's reliance on a single family of products and a single platform technology could negatively affect its results of operations and financial condition.
• The company's stock price may be volatile and fluctuate substantially.

Future Outlook

The company plans to pursue more clinical evidence-based milestones throughout 2024 and into 2025 in connection with evaluating the early pilot commercialization of its percutaneous electrodes, and expects to commence a pivotal clinical trial in mid-2025 to support a specific labeling indication to commercialize the Percutaneous Electrode System in the United States as a treatment for benign thyroid nodules. The company also expects to begin pivotal clinical trials for both the cardiac clamp and catheter in mid-2025.

Management Comments

• Based on our preclinical experience and the potential to significantly improve outcomes for patients in a large and growing market, the Company decided in 2022 to focus its primary efforts on the use of nsPFA energy and the CellFX platform in the treatment of atrial fibrillation and in a select few other markets where it could have a profound positive impact on healthcare for both patients and providers, such as soft tissue ablation.
• We believe our nsPFA technology can provide important advantages over todays thermal modalities in creating these ablation lines.
• We believe CellFX nsPFA technology, which delivers pulses of electrical energy that are each less than a millionth of a second long, can offer similar safety advantages as PFA and may provide improved efficacy advantages based on the circumferential design of our catheter and because it appears CellFX nsPFA technology can create deeper ablations.

Industry Context

The company's focus on atrial fibrillation treatment aligns with the growing prevalence of this condition and the increasing demand for effective ablation technologies. The development of non-thermal ablation methods like nsPFA is a significant trend in the medical device industry, offering potential advantages over traditional thermal methods. The company's entry into the soft tissue ablation market also reflects a broader trend towards minimally invasive procedures.

Comparison to Industry Standards

• Pulse Biosciences is competing with established companies like Abbott, AtriCure, Boston Scientific, Johnson & Johnson (Biosense Webster), and Medtronic in the cardiac ablation market, all of which have greater financial and technical resources.
• The company's nsPFA technology is differentiated from traditional thermal ablation methods and micro-PFA, which are the current standards of care for AF treatment.
• The company's focus on a circumferential ablation catheter design is a unique approach compared to other PFA devices in development.
• The company's early clinical data for its cardiac devices are promising, but further clinical trials are needed to demonstrate safety and efficacy compared to existing technologies.
• The company's percutaneous electrode system for soft tissue ablation is a novel approach, but its commercial success will depend on adoption by surgeons and other physicians.

Legal Proceedings

• The company is involved in an arbitration demand with its former Chief Financial Officer, Sandra Gardiner, seeking severance benefits and other remedies.

Related Party Transactions

• Robert W. Duggan, the company's majority stockholder and Co-Chairman, purchased approximately 88% of the units offered through the 2024 Rights Offering.
• The company entered into a letter agreement with Robert W. Duggan in May 2022, where he agreed to personally provide indemnity coverage for a one-year period, for which the company paid him a fee of $1.0 million.
• The company entered into a loan agreement with Robert W. Duggan in September 2022, which was later terminated through a Securities Purchase Agreement in April 2023.

Stakeholder Impact

• Shareholders have experienced dilution due to the recent rights offering.
• Employees may be affected by potential future cost-cutting measures.
• Customers (surgeons and other physicians) may benefit from the company's innovative technologies.
• Suppliers may be affected by the company's reliance on third-party manufacturers.
• Creditors may be affected by the company's financial performance and ability to repay debts.

Next Steps

• The company will continue its first-in-human study for thyroid nodule treatment.
• The company will continue its multi-site clinical study for the cardiac surgical ablation clamp in the Netherlands.
• The company will continue its clinical study for the CellFX nsPFA 360 Cardiac Catheter in Prague, Czech Republic.
• The company expects to commence pivotal clinical trials for both the cardiac clamp and catheter in mid-2025.
• The company will continue to evaluate the early pilot commercialization of its percutaneous electrodes.

Key Dates

Keywords

Pulse Biosciences, Nano-pulse Stimulation, NPS, nsPFA, atrial fibrillation, AF, soft tissue ablation, CellFX System, cardiac ablation, thyroid nodules, medical devices, FDA clearance, clinical trials